Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition

International Journal of Oncology

Volumn 47, Issue 4, 2015, Pages 1451-1459

  So, Kyeong A ^a   Min, Kyung Jin ^b   Hong, Jin Hwa ^b   Lee, Jae Kwan ^b  

^a Dankook University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Epithelial mesenchymal transition; Gynecologic cancer; Interleukin 6; Invasion; Metastasis

Indexed keywords

CXCL1 CHEMOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE CELL ADHESION MOLECULE; RANTES; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; IL6 PROTEIN, HUMAN;

AMNION; ARTICLE; CANCER GROWTH; CELL INTERACTION; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MESENCHYMAL STEM CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; BIOSYNTHESIS; COCULTURE; ENDOMETRIUM TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; MESENCHYMAL STROMA CELL; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; COCULTURE TECHNIQUES; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT;

EID: 84941009894     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3122     Document Type: Article

References (35)

1. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM and DeClerck YA: Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res 72: 2473-2480, 2012.
2. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, et al: Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 124: 317-326, 2010.
3. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, et al: Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91: 1017-1026, 2006.
4. Prockop DJ, Sekiya I and Colter DC: Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy 3: 393-396, 2001.
5. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE and Kanhai HH: Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22: 1338-1345, 2004.
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147, 1999.
7. Deans RJ and Moseley AB: Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 28: 875-884, 2000.
8. Chen J, Zhang ZG, Li Y, Wang L, Xu YX, Gautam SC, Lu M, Zhu Z and Chopp M: Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res 92: 692-699, 2003.
9. Spaeth E, Klopp A, Dembinski J, Andreeff M and Marini F: Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15: 730-738, 2008.
10. Hombauer H and Minguell JJ: Selective interactions between epithelial tumour cells and bone marrow mesenchymal stem cells. Br J Cancer 82: 1290-1296, 2000.
11. Fierro FA, Sierralta WD, Epuñan MJ and Minguell JJ: Marrowderived mesenchymal stem cells: Role in epithelial tumor cell determination. Clin Exp Metastasis 21: 313-319, 2004.
12. Cho JA, Park H, Lim EH, Kim KH, Choi JS, Lee JH, Shin JW and Lee KW: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol 123: 379-386, 2011.
13. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
14. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I and Salzet M: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291: 59-66, 2010.
15. Lei X, Wang L, Yang J and Sun LZ: TGFbeta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res 2009: 15-24, 2009.
16. Imamura T, Hikita A and Inoue Y: The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis. Breast Cancer 19: 118-124, 2012.
17. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M and Marini F: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4: e4992, 2009.
18. Do TV, Kubba LA, Du H, Sturgis CD and Woodruff TK: Transforming growth factor-beta1, transforming growth factorbeta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 6: 695-705, 2008.
19. Stagg J: Mesenchymal stem cells in cancer. Stem Cell Rev 4: 119-124, 2008.
20. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, Tanaka S, Yasui W and Chayama K: Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 127: 2323-2333, 2010.
21. Albarenque SM, Zwacka RM and Mohr A: Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res (Amst) 7: 163-171, 2011.
22. Lee MY and Shen MR: Epithelial-mesenchymal transition in cervical carcinoma. Am J Transl Res 4: 1-13, 2012.
23. Castilla M, Moreno-Bueno G, Romero-Pérez L, Van De Vijver K, Biscuola M, López-García M, Prat J, Matías-Guiu X, Cano A, Oliva E, et al: Micro-RNA signature of the epithelialmesenchymal transition in endometrial carcinosarcoma. J Pathol 223: 72-80, 2011.
24. Francí C, Takkunen M, Dave N, Alameda F, Gómez S, Rodríguez R, Escriv M, Montserrat-Sentís B, Baró T, Garrido M, et al: Expression of Snail protein in tumor-stroma interface. Oncogene 25: 5134-5144, 2006.
25. Hogan NM, Dwyer RM, Joyce MR and Kerin MJ: Mesenchymal stem cells in the colorectal tumor microenvironment: Recent progress and implications. Int J Cancer 131: 1-7, 2012.
26. Morel AP, Livre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888, 2008.
27. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM and Hall BM: Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28: 2940-2947, 2009.
28. Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelialmesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 9: 1658-1667, 2011.
29. Chen P and Parks WC: Role of matrix metalloproteinases in epithelial migration. J Cell Biochem 108: 1233-1243, 2009.
30. Zeng ZS, Cohen AM and Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20: 749-755, 1999.
31. Thomas GT, Lewis MP and Speight PM: Matrix metalloproteinases and oral cancer. Oral Oncol 35: 227-233, 1999.
32. Kishimoto T: Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res Ther 8 (Suppl 2): S2, 2006.
33. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H and Seiden MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12: 5055-5063, 2006.
34. Shah K: Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 64: 739-748, 2012.
35. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE and Hall BM: Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 21: 3763-3770, 2007.